investor conferences

First Advantage Corporation ($FA) will present at four investor conferences in May-June 2026, with live webcasts available on its investor relations website.

Tarsus reports Q1 2026 XDEMVY sales exceeding $145M, up 85% YoY, while maintaining full-year guidance of $670M-$700M.

TeraWulf ($WULF) announces senior management will participate in investor conferences across New York, London, and California in May 2026, strengthening institutional investor engagement.

Tower Semiconductor to participate in four major investor conferences in May-June 2026, offering one-on-one investor meetings across global markets.

Aduro Clean Technologies announces May 2026 conference participation to showcase pilot operations, commercial facility progress, and new offtake and licensing agreements.

Aduro Clean Technologies will present at five major industry conferences in May 2026, showcasing pilot operations and commercial progress including a licensing agreement and oil purchase letter of intent.

Viking Therapeutics to present at two major biotech conferences in April 2026, conducting investor meetings in New York and Boston.

Lightbridge Corporation's CEO will present at three major investor conferences in April 2026, highlighting advanced nuclear fuel technology and strategic positioning.

Aduro Clean Technologies CEO to present at three investor conferences in April 2026, detailing progress on pilot plant operations and industrial deployment plans.

Aduro Clean Technologies CEO Ofer Vicus will present at three investor conferences in April 2026, highlighting pilot operations and First-of-a-Kind facility development progress.

Oculis announces March 2026 investor conference participation, showcasing pipeline advances including Privosegtor's optic neuritis breakthrough designation and anticipated Phase 3 readouts.

Oculis plans March 2026 investor conferences highlighting six pivotal clinical readouts, including Privosegtor's breakthrough optic neuritis program and OCS-01 Phase 3 results expected Q2 2026.

Oculis files 2025 audited financial statements with SEC via Form 20-F and announces investor conference participation, signaling transparent capital markets engagement.

$OXB schedules June 2026 Capital Markets Day and four investor conferences, releasing FY2025 results March 26 to boost institutional engagement.

Immunocore Holdings announced presentations at five major investor conferences in March 2026, showcasing its commercial-stage biotech platform and pipeline to institutional investors.

LeMaitre Vascular will present at five major healthcare investment conferences in March 2026, engaging with institutional investors and analysts about corporate strategy and growth opportunities.

Minerals Technologies to present at four major investor conferences in March 2026, with CEO and CFO discussing strategic direction and financial performance.

Aquestive Therapeutics will present at four major healthcare investor conferences in March 2026, updating investors on its clinical pipeline and strategic initiatives.